WuXi XDC Cayman Inc. (HKG:2268)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 69.07B +71.0% |
| Revenue (ttm) | 6.61B +46.7% |
| Net Income | 1.65B +38.4% |
| EPS | 1.25 +34.9% |
| Shares Out | 1.26B |
| PE Ratio | 43.97 |
| Forward PE | 29.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,233,851 |
| Average Volume | 3,266,053 |
| Open | 55.30 |
| Previous Close | 54.80 |
| Day's Range | 54.20 - 57.35 |
| 52-Week Range | 34.55 - 85.50 |
| Beta | -0.75 |
| RSI | 36.21 |
| Earnings Date | Aug 18, 2026 |
About WuXi XDC Cayman
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, m... [Read more]
Financial Performance
In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.
Financial numbers in CNY Financial StatementsNews
Akari Therapeutics Announces Strategic Partnership With WuXi XDC
(RTTNews) - Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody-drug conjugates (ADCs) with novel RNA splicing modulating payloads, announced a strategic part...
WuXi XDC Cayman Earnings Call Transcript: H2 2025
2025 saw record revenue and profit growth, a surge in project signings, and a backlog exceeding $1.5 billion. Strategic acquisitions and capacity expansions position the company for 30%-35% CAGR, with commercial manufacturing revenue set to rise in coming years.
US reshoring drive casts shadow over China’s contract drug makers: analyst
Chinese contract drug makers – including WuXi AppTec, WuXi Biologics and WuXi XDC – face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house and reconfigu...